See more : The Mosaic Company (MOS) Income Statement Analysis – Financial Results
Complete financial analysis of Cullinan Oncology, Inc. (CGEM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cullinan Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Talen Energy Corporation (TLN) Income Statement Analysis – Financial Results
- Companhia Catarinense de Águas e Saneamento – CASAN (CASN4.SA) Income Statement Analysis – Financial Results
- Markor International Home Furnishings Co., Ltd. (600337.SS) Income Statement Analysis – Financial Results
- Shaanxi Baoguang Vacuum Electric Device Co., Ltd. (600379.SS) Income Statement Analysis – Financial Results
- Micron Solutions, Inc. (MICR) Income Statement Analysis – Financial Results
Cullinan Oncology, Inc. (CGEM)
About Cullinan Oncology, Inc.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 18.94M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 310.00K | 93.00K | 53.00K | 62.00K | 70.00K | 43.00K |
| Gross Profit | -310.00K | -93.00K | 18.89M | -62.00K | -70.00K | -43.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 99.72% | 0.00% | 0.00% | 0.00% |
| Research & Development | 148.16M | 91.95M | 57.75M | 43.21M | 16.79M | 9.58M |
| General & Administrative | 42.49M | 40.19M | 29.15M | 17.12M | 5.48M | 5.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 42.49M | 40.19M | 29.15M | 17.12M | 5.48M | 5.00M |
| Other Expenses | 440.00K | 57.00K | -8.00K | -11.00K | -4.00K | 0.00 |
| Operating Expenses | 191.09M | 132.14M | 86.90M | 60.34M | 22.27M | 14.59M |
| Cost & Expenses | 191.09M | 132.14M | 86.90M | 60.34M | 22.27M | 14.59M |
| Interest Income | 21.63M | 6.61M | 477.00K | 888.00K | 620.00K | 397.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 310.00K | 93.00K | 53.00K | 62.00K | 70.00K | 43.00K |
| EBITDA | -190.34M | 151.41M | -67.90M | -60.27M | -22.20M | -14.54M |
| EBITDA Ratio | 0.00% | 0.00% | -358.73% | 0.00% | 0.00% | 0.00% |
| Operating Income | -191.09M | 144.65M | -67.95M | -60.34M | -22.27M | -14.59M |
| Operating Income Ratio | 0.00% | 0.00% | -358.73% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 21.87M | 6.67M | 469.00K | 877.00K | 616.00K | 397.00K |
| Income Before Tax | -169.22M | 151.32M | -67.49M | -59.46M | -21.65M | -14.19M |
| Income Before Tax Ratio | 0.00% | 0.00% | -356.25% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -14.12M | 42.12M | -2.45M | -8.61M | -1.62M | 397.00K |
| Net Income | -153.16M | 111.21M | -65.04M | -50.85M | -20.04M | -14.19M |
| Net Income Ratio | 0.00% | 0.00% | -343.35% | 0.00% | 0.00% | 0.00% |
| EPS | -3.69 | 2.46 | -1.47 | -1.17 | -0.46 | -1.24 |
| EPS Diluted | -3.69 | 2.38 | -1.47 | -1.17 | -0.46 | -1.24 |
| Weighted Avg Shares Out | 41.51M | 45.16M | 44.29M | 43.52M | 43.52M | 11.45M |
| Weighted Avg Shares Out (Dil) | 41.55M | 46.64M | 44.29M | 43.52M | 43.52M | 11.45M |
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Source: https://incomestatements.info
Category: Stock Reports